Actavia Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
May 20, 2024 at 05:10 pm
Share
Actavia Life Sciences, Inc. reported earnings results for the second quarter and six months ended March 31, 2024. For the second quarter, the company reported net loss was USD 0.095518 million compared to USD 4.13 million a year ago.
For the six months, net loss was USD 0.243155 million compared to USD 4.28 million a year ago.
Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.
ACTAVIA LIFE SCIENCES, INC. 